Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Shares
-
Shares outstanding
-
124,058,172
-
Number of holders
-
52
-
Total 13F shares, excl. options
-
34,475,113
-
Shares change
-
+599,788
-
Total reported value, excl. options
-
$274,062,429
-
Value change
-
+$4,571,679
-
Put/Call ratio
-
74.05%
-
Number of buys
-
29
-
Number of sells
-
-12
-
Price
-
$7.95
Significant Holders of ADC Therapeutics SA - Common Shares (ADCT) as of Q2 2022
59 filings reported holding ADCT - ADC Therapeutics SA - Common Shares as of Q2 2022.
ADC Therapeutics SA - Common Shares (ADCT) has 52 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34,475,113 shares
of 124,058,172 outstanding shares and own 27.79% of the company stock.
Largest 10 shareholders include FMR LLC (7,681,046 shares), Redmile Group, LLC (7,512,029 shares), JPMORGAN CHASE & CO (3,453,672 shares), ALLIANCEBERNSTEIN L.P. (2,961,624 shares), PRICE T ROWE ASSOCIATES INC /MD/ (1,961,210 shares), EVENTIDE ASSET MANAGEMENT, LLC (1,879,959 shares), GCM Grosvenor Holdings, LLC (1,298,012 shares), PICTET ASSET MANAGEMENT SA (1,295,018 shares), Vantage Consulting Group Inc (1,186,215 shares), and Walleye Capital LLC (888,700 shares).
This table shows the top 52 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.